Abstract
Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.
Original language | English |
---|---|
Pages (from-to) | 59-68 |
Number of pages | 10 |
Journal | Future Oncology |
Volume | 10 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 1 2014 |
Keywords
- leiomyosarcoma
- liposarcoma
- sarcoma
- second-line treatment
- STS
- trabectedin
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Medicine(all)